SOX9 and cancer: p62 [20–32] and SOX9 [33–39] are overexpressed in both PCa and BCa patient tumor tissue, correlate with disease progression and treatment resistance, and support BCa and PCa tumor growth in vivo, indicating that these proteins are functional in cancer and clinically relevant.